These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35960238)

  • 1. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
    Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
    Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
    Wiese AD; Griffin MR; Zhu Y; Mitchel EF; Grijalva CG
    Vaccine; 2016 Dec; 34(50):6243-6249. PubMed ID: 27832918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.
    Saxena S; Atchison C; Cecil E; Sharland M; Koshy E; Bottle A
    J Infect; 2015 Oct; 71(4):428-36. PubMed ID: 26159503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Clin Vaccine Immunol; 2013 Oct; 20(10):1524-30. PubMed ID: 23925887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
    Syrogiannopoulos GA; Michoula AN; Tsimitselis G; Vassiou K; Chryssanthopoulou DC; Grivea IN
    Infect Dis (Lond); 2016 Oct; 48(10):749-53. PubMed ID: 27320108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; Elberse KE; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2016 Feb; 34(8):1077-85. PubMed ID: 26778420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization.
    Pelton SI; Bornheimer R; Doroff R; Shea KM; Sato R; Weycker D
    Clin Infect Dis; 2019 May; 68(11):1831-1838. PubMed ID: 30239637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.